# MTX-531-001 Phase 1 Study in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07874880/  
OnCo record `nct07874880` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MTX-531 run by MEKanistic Therapeutics, Inc., not yet recruiting.

## Summary

MTX-531-001 Phase 1 Study in Advanced Solid Tumors is a phase 1 interventional study registered as NCT07874880 by MEKanistic Therapeutics, Inc., with 71 participants planned, started 2026-10-20. Conditions recorded: Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer, Pan-RAS and BRAF Wild-type Advanced, Metastatic Colorectal Cancer (CRC) and Head and Neck Squamous Cell Carcinoma. Interventions recorded: MTX-531.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07874880
- Phase: 1
- Setting: First-in-Human, Phase 1, Open-label Study to Evaluate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of MTX-531, a Dual EGFR/PI3K Inhibitor, as Monotherapy in Adults With Advanced Solid Tumors
- Sponsor: MEKanistic Therapeutics, Inc.
- Enrolled: 71

## Sources

- ClinicalTrials.gov NCT07874880: https://clinicaltrials.gov/study/NCT07874880

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [MTX-531](https://onco.cc/drugs/mtx-531/)
- companies: [MEKanistic Therapeutics](https://onco.cc/companies/mekanistic-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07874880.json